Tim Jasper Knotnerus bought $94k of AGMB
Chief Executive Officer at AgomAb Therapeutics NV. 11,000 shares at an average of $8.58, traded Oct 5, 2026, filed Oct 7, 2026.
Score components
- +25RoleCEO
- +10Trade size$94k at market
- +10Relative to holdingsHoldings up 102%
- 0Price contextNo price history yet
- +15Cluster3 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0002120886-26-000001, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 5, 2026 | POpen-market purchase Common shares | +6,000 | $8.48 | $51k | 16,823 | 5 d ago |
| Oct 6, 2026 | POpen-market purchase Common shares | +5,000 | $8.70 | $44k | 21,823 | 5 d ago |
Related signals
Other insiders at AgomAb Therapeutics NV and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 51Moderate | AgomAb Therapeutics NV | David R Epstein director | $45k 5,000 shares | +50% | |
| 47Moderate | AgomAb Therapeutics NV | David R Epstein director | $86k 10,000 shares | - | |
| 54Moderate | AgomAb Therapeutics NV | Pierre Thadee Victor Kemula Chief Financial Officer | $86k 10,000 shares | - |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.